Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study.

Jovanovich A, You Z, Isakova T, Nowak K, Cheung A, Wolf M, Chonchol M, Kendrick J.

Am J Nephrol. 2019;49(4):263-270. doi: 10.1159/000497445. Epub 2019 Feb 28.

PMID:
30820005
2.

Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study.

Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK.

J Am Soc Nephrol. 2016 Jan;27(1):227-37. doi: 10.1681/ASN.2014101009. Epub 2015 May 13.

3.

Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.

Scialla JJ, Parekh RS, Eustace JA, Astor BC, Plantinga L, Jaar BG, Shafi T, Coresh J, Powe NR, Melamed ML.

Am J Nephrol. 2015;42(1):25-34. doi: 10.1159/000438999. Epub 2015 Aug 20.

4.

Longitudinal FGF23 Trajectories and Mortality in Patients with CKD.

Isakova T, Cai X, Lee J, Xie D, Wang X, Mehta R, Allen NB, Scialla JJ, Pencina MJ, Anderson AH, Talierco J, Chen J, Fischer MJ, Steigerwalt SP, Leonard MB, Hsu CY, de Boer IH, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

J Am Soc Nephrol. 2018 Feb;29(2):579-590. doi: 10.1681/ASN.2017070772. Epub 2017 Nov 22.

5.

Phosphate control in reducing FGF23 levels in hemodialysis patients.

Rodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, Pendon-Ruiz de Mier MV, Agüera ML, Muñoz-Castañeda JR, Soriano S, Caravaca F, Alvarez-Lara MA, Felsenfeld A, Aljama P, Rodriguez M.

PLoS One. 2018 Aug 7;13(8):e0201537. doi: 10.1371/journal.pone.0201537. eCollection 2018.

6.

Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study.

Kim HJ, Kim H, Shin N, Na KY, Kim YL, Kim D, Chang JH, Song YR, Hwang YH, Kim YS, Ahn C, Lee J, Oh KH; Representing the Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect Of iPTH Level (CUPID) Study Group.

BMC Nephrol. 2013 May 25;14:112. doi: 10.1186/1471-2369-14-112.

7.
8.

Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.

Montford JR, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Kendrick J; HOST Investigators.

Am J Nephrol. 2013;37(3):183-90. doi: 10.1159/000346941. Epub 2013 Feb 20.

9.

Baseline FGF23 is Associated with Cardiovascular Outcome in Incident PD Patients.

Kim HJ, Park M, Park HC, Jeong JC, Kim DK, Joo KW, Hwang YH, Yang J, Ahn C, Oh KH.

Perit Dial Int. 2016 Jan-Feb;36(1):26-32. doi: 10.3747/pdi.2013.00343. Epub 2014 Sep 2.

10.

Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.

Sugimoto H, Ogawa T, Iwabuchi Y, Otsuka K, Nitta K.

Int Urol Nephrol. 2014 Jan;46(1):99-106. doi: 10.1007/s11255-013-0386-2. Epub 2013 Jan 25.

PMID:
23355029
11.

Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).

Westerberg PA, Tivesten Å, Karlsson MK, Mellström D, Orwoll E, Ohlsson C, Larsson TE, Linde T, Ljunggren Ö.

BMC Nephrol. 2013 Apr 15;14:85. doi: 10.1186/1471-2369-14-85.

12.

Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis.

Zaritsky J, Rastogi A, Fischmann G, Yan J, Kleinman K, Chow G, Gales B, Salusky IB, Wesseling-Perry K.

Nephrol Dial Transplant. 2014 Feb;29(2):437-41. doi: 10.1093/ndt/gft382. Epub 2013 Sep 5.

13.

Hemodialysis is associated with higher serum FGF23 level when compared with peritoneal dialysis.

Bi S, Liang Y, Cheng L, Wang Y, Wang T, Han Q, Zhang A.

Int Urol Nephrol. 2017 Sep;49(9):1653-1659. doi: 10.1007/s11255-017-1605-z. Epub 2017 Apr 28.

PMID:
28455658
14.

Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.

Bielesz BO, Hecking M, Plischke M, Cejka D, Kieweg H, Haas M, Marculescu R, Hörl WH, Bieglmayer C, Sunder-Plassmann G.

Clin Biochem. 2014 Sep;47(13-14):1316-9. doi: 10.1016/j.clinbiochem.2014.06.009. Epub 2014 Jun 21.

PMID:
24956265
15.

Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1989-1998. Epub 2016 Aug 25.

16.

Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis.

Schwantes-An TH, Liu S, Stedman M, Decker BS, Wetherill L, Edenberg HJ, Vatta M, Foroud TM, Chertow GM, Moe SM.

Am J Nephrol. 2019;49(2):125-132. doi: 10.1159/000496060. Epub 2019 Jan 22.

PMID:
30669147
17.

Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?

Nowak A, Artunc F, Serra AL, Pollock E, Krayenbühl PA, Müller C, Friedrich B.

Kidney Blood Press Res. 2015;40(3):266-76. doi: 10.1159/000368502. Epub 2015 May 21.

18.

Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.

Sánchez Fructuoso AI, Maestro ML, Calvo N, De La Orden V, Pérez Flores I, Vidaurreta M, Valero R, Fernández-Pérez C, Barrientos A.

Transplant Proc. 2012 Nov;44(9):2551-4. doi: 10.1016/j.transproceed.2012.09.070.

PMID:
23146451
19.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

PMID:
26059012
20.

Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.

Brandenburg VM, Kleber ME, Vervloet MG, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H.

Atherosclerosis. 2014 Nov;237(1):53-9. doi: 10.1016/j.atherosclerosis.2014.08.037. Epub 2014 Aug 28.

PMID:
25200615

Supplemental Content

Support Center